CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.95B, above the global median of $1.18B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.95BUSDvs all stocks (USD)
Revenue (TTM)
54.59MUSDvs all stocks (USD)
Profit Margin
-287.84%vs Biotechnology peers
Beta
1.15xvs all stocks
52-Week Change
-3.16%vs all stocks
Market Capitalization
1.95BUSDvs all stocks (USD)
Enterprise Value
1.40BUSDvs all stocks (USD)
Forward P/E
-5.60xvs Biotechnology peers
Price to Sales (TTM)
35.69xvs Biotechnology peers
Price to Book (MRQ)
2.16xvs Biotechnology peers
Enterprise to Revenue
25.64xvs Biotechnology peers
Enterprise to EBITDA
-10.77xvs Biotechnology peers
Profit Margin
-287.84%vs Biotechnology peers
Operating Margin
-412.23%vs Biotechnology peers
Return on Assets (TTM)
-12.54%vs Biotechnology peers
Return on Equity (TTM)
-35.76%vs Biotechnology peers
Revenue (TTM)
54.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.25USDUpdated Sep 28, 2026Quarterly Revenue Growth
-9.30%vs Biotechnology peers
Gross Profit (TTM)
54.59MUSDvs all stocks (USD)
EBITDA (TTM)
-129.95MUSDvs all stocks (USD)
Net Income (TTM)
-157.13MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.34%vs Biotechnology peers
Operating Cash Flow (TTM)
-233.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-134.77MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
55.23MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
0.00USDFY2025 · Dec 31, 2025Gross Profit
55.23MUSDFY2025 · Dec 31, 2025Operating Income
-130.77MUSDvs all stocks (USD)
Pre-tax Income
-155.49MUSDFY2025 · Dec 31, 2025Income Tax Expense
-138.00KUSDFY2025 · Dec 31, 2025Net Income
-164.08MUSDFY2025 · Dec 31, 2025EBIT
-129.30MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-118.95MUSDFY2025 · Dec 31, 2025Research & Development
117.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
68.67MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.44MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
-9.73USDFY2025 · Dec 31, 2025EPS (Diluted)
-9.73USDFY2025 · Dec 31, 2025Basic Shares Outstanding
16.87MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
16.87MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-164.08MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-210.38MUSDFY2025 · Dec 31, 2025Free Cash Flow
-210.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
15.12MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-164.08MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.03MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.65MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-28.75MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-625.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-30.61MUSDFY2025 · Dec 31, 2025Capital Expenditures
-171.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-697.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-285.01MUSDFY2025 · Dec 31, 2025Sale of Investments
284.68MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.20MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.15MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
179.70MUSDFY2025 · Dec 31, 2025Shares Outstanding
34.13MSharesUpdated Sep 28, 2026Float Shares
28.54MSharesUpdated Sep 28, 2026Shares Short
5.74MSharesUpdated Sep 28, 2026Short Ratio
8.82daysvs all stocks
Short % of Shares Outstanding
18.52%vs all stocks
% Held by Insiders
0.35%vs all stocks
% Held by Institutions
106.96%vs all stocks
Total Cash (MRQ)
684.34MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
20.04USDUpdated Sep 28, 2026Total Debt (MRQ)
135.93MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1505xvs Biotechnology peers
Current Ratio (MRQ)
10.42xvs Biotechnology peers
Book Value per Share (MRQ)
26.46USDUpdated Sep 28, 2026Total Assets
280.41MUSDvs all stocks (USD)
Total Current Assets
266.27MUSDFY2025 · Dec 31, 2025Total Liabilities
190.57MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.14MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
137.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
53.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
15.12MUSDFY2025 · Dec 31, 2025Other Short-term Investments
230.64MUSDFY2025 · Dec 31, 2025Accounts Payable
10.77MUSDFY2025 · Dec 31, 2025Short-term Debt
20.50MUSDFY2025 · Dec 31, 2025Long-term Debt
65.26MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
71.78MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.76BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
89.83MUSDvs all stocks (USD)
Treasury Stock
0.00USDFY2025 · Dec 31, 202552-Week Low
33.40USDUpdated Sep 28, 202652-Week High
109.00USDUpdated Sep 28, 202652-Week Change
-3.16%vs all stocks
Beta
1.15xvs all stocks
50-Day MA
70.87USDUpdated Sep 28, 2026200-Day MA
65.44USDUpdated Sep 28, 2026Avg 10-Day Volume
1.86MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.03MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-6.12USDUpdated Sep 28, 2026Other Income / Expense
-8.97MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 35.69Revenue Growth YoY: -0.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.95B, above the global median of $1.18BNotable
Market cap (USD): 1,948,199,271Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule